June 22, 2016
Takeda Pharmaceutical has initiated dosing in a PIIb field efficacy trial in the US for TAK-214, which is the world’s only norovirus vaccine candidate in human clinical trials, the company said on June 21. The intramuscular vaccine candidate is designed...read more